Apogee Pipeline Update: Positive Interim Phase 1 Results From the APG990 Healthy Volunteer Trial Unlock Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Apogee Therapeutics, Inc’s APG990 exceeded trial objectives and demonstrated an approximately 60-day half-life in interim Phase 1 results from its first-in-human trial. APG990 is a novel, subcutaneous (SQ), half-life-extended monoclonal antibody (mAb) that targets OX40L, which is positioned further upstream in the inflammatory pathway than interleukin (IL)-13. APG990 interim Phase 1 pharmacokinetic (PK) data showed […]